支架置入联合药物治疗与单纯药物治疗对症状性颅内狭窄患者卒中和死亡风险的影响:CASSISS随机临床试验
CASSISS研究为多中心、开放标签、结局评估者盲法的随机临床试验,在中国8个中心纳入380例症状性重度颅内动脉粥样硬化性狭窄(70%-99%)患者,随机接受支架置入联合药物治疗(n=176)或单纯药物治疗(n=182)。主要终点为30天内卒中或死亡或30天后至1年内责任血管区卒中的复合终点,两组无显著差异(8.0% vs 7.2%;HR 1.10,95%CI 0.52-2.35;P=0.82)。5个预设次要终点均无显著差异,3年死亡率两组分别为4.4%和1.3%(HR 3.75,95%CI 0.77-18.13;P=0.08)。作者认为研究结果不支持对症状性重度颅内动脉粥样硬化性狭窄患者在药物治疗基础上加用经皮腔内血管成形术和支架置入。
要点
- 主要终点(30天内卒中或死亡或30天后至1年内责任血管区卒中):支架联合药物组8.0%(14/176) vs 单纯药物组7.2%(13/181),差异0.4%(95%CI -5.0%至5.9%),HR 1.10(95%CI 0.52-2.35),P=0.82
- 2年责任血管区卒中:支架联合药物组9.9%(17/171) vs 单纯药物组9.0%(16/178),差异0.7%(95%CI -5.4%至6.7%),HR 1.10(95%CI 0.56-2.16),P=0.80
- 3年责任血管区卒中:支架联合药物组11.3%(19/168) vs 单纯药物组11.2%(19/170),差异-0.2%(95%CI -7.0%至6.5%),HR 1.00(95%CI 0.53-1.90),P>0.99
- 3年死亡率:支架联合药物组4.4%(7/160) vs 单纯药物组1.3%(2/159),差异3.2%(95%CI -0.5%至6.9%),HR 3.75(95%CI 0.77-18.13),P=0.08
- 作者结论:在症状性重度颅内动脉粥样硬化性狭窄患者中,经皮腔内血管成形术和支架置入联合药物治疗相比单纯药物治疗未显著改善主要终点,研究结果不支持加用支架置入
适用人群与场景
- 短暂性脑缺血发作或非致残性、非穿支(定义为非脑干或非基底节终末动脉)供血区缺血性卒中,归因于重度颅内狭窄(70%-99%),且距最近一次缺血症状发作超过3周的患者
- 年龄均值56.3岁,男性263例(73.5%);来自中国8个中心
诊断标准与关键阈值
- 重度颅内动脉粥样硬化性狭窄定义为70%-99%
- 非穿支 territory 定义为非脑干或非基底节终末动脉供血区
处置流程与药物剂量
- 药物治疗包括双联抗血小板治疗90天,此后单一抗血小板治疗,以及卒中危险因素控制
- 支架联合药物组在药物治疗基础上接受经皮腔内血管成形术和支架置入(n=176)
研究设计与关键结果
- 多中心、开放标签、结局评估者盲法随机临床试验,中国8个中心,2014年3月5日至2016年11月10日招募380例患者,随访3年(最终随访2019年11月10日)
- 随机分组:支架联合药物组n=176,单纯药物组n=182;358例确认符合标准(平均年龄56.3岁;男性263例[73.5%]),343例(95.8%)完成试验
- 主要终点(30天内卒中或死亡或30天后至1年内责任血管区卒中):支架联合药物组8.0%(14/176) vs 单纯药物组7.2%(13/181),差异0.4%(95%CI -5.0%至5.9%),HR 1.10(95%CI 0.52-2.35),P=0.82
- 2年责任血管区卒中:支架联合药物组9.9%(17/171) vs 单纯药物组9.0%(16/178),差异0.7%(95%CI -5.4%至6.7%),HR 1.10(95%CI 0.56-2.16),P=0.80
- 3年责任血管区卒中:支架联合药物组11.3%(19/168) vs 单纯药物组11.2%(19/170),差异-0.2%(95%CI -7.0%至6.5%),HR 1.00(95%CI 0.53-1.90),P>0.99
- 3年死亡率:支架联合药物组4.4%(7/160) vs 单纯药物组1.3%(2/159),差异3.2%(95%CI -0.5%至6.9%),HR 3.75(95%CI 0.77-18.13),P=0.08
- 5个预设次要终点均无显著差异
证据类型、等级与局限
- 证据类型:多中心、开放标签、结局评估者盲法随机临床试验
- 试验注册:ClinicalTrials.gov标识符NCT01763320
- 局限:原文未报告局限性
对床旁实践的改变
- 作者结论:在症状性重度颅内动脉粥样硬化性狭窄患者中,经皮腔内血管成形术和支架置入联合药物治疗相比单纯药物治疗未显著降低30天内卒中或死亡或30天后至1年内责任血管区卒中风险,研究结果不支持加用支架置入
指南或共识出处
- CASSISS随机临床试验,发表于JAMA,试验注册号NCT01763320
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Prior randomized trials have generally shown harm or no benefit of stenting added to medical therapy for patients with symptomatic severe intracranial atherosclerotic stenosis, but it remains uncertain as to whether refined patient selection and more experienced surgeons might result in improved outcomes.
OBJECTIVE: To compare stenting plus medical therapy vs medical therapy alone in patients with symptomatic severe intracranial atherosclerotic stenosis.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, open-label, randomized, outcome assessor-blinded trial conducted at 8 centers in China. A total of 380 patients with transient ischemic attack or nondisabling, nonperforator (defined as nonbrainstem or non-basal ganglia end artery) territory ischemic stroke attributed to severe intracranial stenosis (70%-99%) and beyond a duration of 3 weeks from the latest ischemic symptom onset were recruited between March 5, 2014, and November 10, 2016, and followed up for 3 years (final follow-up: November 10, 2019).
INTERVENTIONS: Medical therapy plus stenting (n = 176) or medical therapy alone (n = 182). Medical therapy included dual-antiplatelet therapy for 90 days (single antiplatelet therapy thereafter) and stroke risk factor control.
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of stroke or death within 30 days or stroke in the qualifying artery territory beyond 30 days through 1 year. There were 5 secondary outcomes, including stroke in the qualifying artery territory at 2 years and 3 years as well as mortality at 3 years.
RESULTS: Among 380 patients who were randomized, 358 were confirmed eligible (mean age, 56.3 years; 263 male [73.5%]) and 343 (95.8%) completed the trial. For the stenting plus medical therapy group vs medical therapy alone, no significant difference was found for the primary outcome of risk of stroke or death (8.0% [14/176] vs 7.2% [13/181]; difference, 0.4% [95% CI, -5.0% to 5.9%]; hazard ratio, 1.10 [95% CI, 0.52-2.35]; P = .82). Of the 5 prespecified secondary end points, none showed a significant difference including stroke in the qualifying artery territory at 2 years (9.9% [17/171] vs 9.0% [16/178]; difference, 0.7% [95% CI, -5.4% to 6.7%]; hazard ratio, 1.10 [95% CI, 0.56-2.16]; P = .80) and 3 years (11.3% [19/168] vs 11.2% [19/170]; difference, -0.2% [95% CI, -7.0% to 6.5%]; hazard ratio, 1.00 [95% CI, 0.53-1.90]; P > .99). Mortality at 3 years was 4.4% (7/160) in the stenting plus medical therapy group vs 1.3% (2/159) in the medical therapy alone group (difference, 3.2% [95% CI, -0.5% to 6.9%]; hazard ratio, 3.75 [95% CI, 0.77-18.13]; P = .08).
CONCLUSIONS AND RELEVANCE: Among patients with transient ischemic attack or ischemic stroke due to symptomatic severe intracranial atherosclerotic stenosis, the addition of percutaneous transluminal angioplasty and stenting to medical therapy, compared with medical therapy alone, resulted in no significant difference in the risk of stroke or death within 30 days or stroke in the qualifying artery territory beyond 30 days through 1 year. The findings do not support the addition of percutaneous transluminal angioplasty and stenting to medical therapy for the treatment of patients with symptomatic severe intracranial atherosclerotic stenosis.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01763320.
参考来源
- Gao P, Wang T, Wang D, et al. Effect of Stenting Plus Medical Therapy vs Medical Therapy Alone on Risk of Stroke and Death in Patients With Symptomatic Intracranial Stenosis: The CASSISS Randomized Clinical Trial. JAMA. 2022. PMID: 35943472. doi:10.1001/jama.2022.12000
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。